Dexrazoxane (DEX) prevents the formation of free radical, lipid peroxidation and cardiotoxicity caused by anthracyclines. Due to a concern about its possible interference with anthracyclin cytotoxicity, the in vitro effect of DEX on daunorubicin (DNR) cytotoxicity, cell cycle and induction of apoptosis by annexin-V was investigated. The sensitivity to DEX, DNR and their combination was tested by the MTT assay in human promyelocytic leukemia HL-60, the erythroid blast crisis CML K562 cell lines and in 45 children with ALL and AML. Cell cycle analysis and annexin-V expression were performed by flow cytometry. It has been observed that DEX itself weakly, but significantly caused cytotoxicity in both cell lines and in patient samples, especially in initial ALL samples. DEX sensitized K562 and HL60, but not patient samples, to cytotoxicity of DNR. The percentage of necrotic/apoptotic cells, as detected in cell cycle analysis and annexin V staining, was higher after exposure to DEX ± DNR, when compared to respective samples not treated with DEX, in both cell lines but not in patient samples. Expression of annexin V induced by DEX in both cell lines was enlarged, regardless of the presence of DNR. This difference was not observed in patient samples, however, the number of cells expressing annexin V was higher after exposure to DEX ± DNR in comparison to respective samples not treated with DEX. In conclusion, it seems that DEX possibly has no impact on the sensitivity of childhood leukemic blasts to DNR, however, has weak cytotoxic properties itself. Leukemia (2002) 16, 820-825.
Introduction
The bisdioxopiperazines, including dexrazoxane (DEX), are catalytic or noncleavable complex-forming inhibitors of DNA topoisomerase II that do not produce DNA strand breaks. 1 It has been suggested that the product of dexrazoxane (ICRF-187) hydrolysis, ICRF-198, chelates and removes free iron and iron associated with the doxorubicin-iron complex and, therefore, prevents the formation of free radical, lipid peroxidation and cardiotoxicity. As an inhibitor of topoisomerase II, it prevents the inactivation of cytochrome C oxidase by Fe3+ and increases the levels of transferrin receptor mRNA and cellular iron uptake. 2 However, there is a concern about its possible interference with anthracyclin cytotoxicity. In a study of the effect of DEX and a radical scavenger, butylated hydroxyanisole (BHA) on in vitro cytotoxicity of topo-II inhibitors, daunorubicin (DNR) and etoposide (VP-16) in leukemia cells from children, it has been observed that DEX increased resistance to DNR and VP-16 in AML and T-ALL, however, it did not affect apoptosis induction in T-ALL. 3 In an ongoing study, the effect of DEX on in vitro DNR cytotoxicity, cell cycle and induction of apoptosis by annexin V in leukemia cells from children with ALL and AML, was investigated. 
Materials and methods

Cell culture and patient samples
The cytotoxicity of DEX, DNR and their combination was tested in human promyelocytic leukemia HL60, and the erythroid blast crisis CML K562 cell lines (both were a kind gift of Dr Alina Grzanka, Department of Pathology, Medical University, Bydgoszcz) and in 45 children, including 38 ALL (28 de novo, 10 relapsed) and seven AML children. The median age of patients was 8 years (range 0.4-18 years). Leukemic cells were isolated by Ficoll-Hypaque (Aqua Medica, Łó dź, Poland) density gradient separation and resuspended in RPMI-1640 (Sigma-Aldrich, Schnelldorf, Germany) with 20% fetal calf serum (FCS; Gibco BRL Life Technologies, UK). The morphology was evaluated from cytospine slide preparations with May-Grunwald-Giemsa staining, and the viability was assessed by trypan blue dye exclusion. Only fresh leukemic samples were taken for the study and the percentage of blasts in the sample was over 90%.
Drugs
DNR (Cerubidine) was purchased from Bellon Rhone-Poulenc-Rhorer (Neuilly Sur Seine, France) and DEX (Cardioxan) from Chiron BV (Amsterdam, The Netherlands). DEX was used in concentration always in the ratio of 20:1 to DNR, as indicated by the manufacturer. Control concentration of DEX without DNR was 20 g/ml.
MTT viability assays
Cytotoxicity was measured by a viability and cell proliferation assay by measuring the ability of the cells to cleave the soluble compound 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT; Serva, Heidelberg, Germany) into an insoluble salt. The ability of cells to cleave MTT is indicative of the degree of mitochondrial/cellular respiration within those cells. Conditions of the assay were similar as described previously. 4 Briefly, cells were incubated for 4 days with various concentrations of DNR (0.001-1 g/ml), DEX (20 g/ml) or in a combination of both drugs for 4 days in 96-well plates. Ten l of MTT (5 g/ml) was added to each well. The reaction was stopped after 4 h incubation by adding 100 l of 0.04 N HCl in isopropanol (Sigma-Aldrich), and the optical density (OD) was measured at 550 nm (reference wavelength 720 nm) with a Multiscan Bichromatic plate reader (Asys Hitech, Eugendorf, Austria) and DigiWin software (Asys Hitech). All experiments were performed in triplicate, and the data were confirmed to be reproducible. The cytotoxicity was expressed as LC50, lethal concentration for 50% of cells. When LC50 for DNR was above 1 g/ml, the percentage of cells surviving in the highest concentration was calculated.
Cell cycle analysis
For DNA content analysis, cells were stained with hypotonic propidium iodine solution (20 g/ml; DNA-Prep Kit, Lot number PN 6607055; Coulter, Miami, FL, USA) and 20 000 events were analyzed with an Epics XL flow cytometer (Coulter) after 96 h of incubation. This flow cytometer is equipped with an argon laser with an excitation wavelength of 488 nm. Cell cycle was calculated by Multicycle software (Phoenix Flow Systems, San Diego, CA, USA). The percentage of cells in the G1, G2 and S phase was expressed as mean ± s.d.
Apoptotic assay using annexin V/propidium iodide
Apoptotic cells were determined by double staining with annexin V (FITC) and propidium iodide (PI) after 48 h of incubation by using a staining kit purchased from PharMingen (lot number 556547; Becton Dickinson Biosciences, San Diego, CA, USA). Five thousand to 10 000 events were analyzed on Epics XL flow cytometer (Coulter) and % apoptosis was determined using System II v 3.0 software (Coulter).
Statistical analysis
Results are given as mean values ± s.d. and also as median values + quartiles. For continuous variables, the MannWhitney U test was used for unpaired comparisons and the Wilcoxon signed rank test was used for paired comparisons. Correlations were analyzed by Spearman's rho coefficient.
The mean values were compared with Student's t-test. All reported P values are two-sided. Differences were considered to be statistically significant when P values were Ͻ0.05.
Figure 1
K562 and HL60 cell line survival without any drug, with DEX 20 g/ml, DNR 1 g/ml, and the combination of DNR 1 g/ml plus DEX 20 g/ml. The values are the mean of four experiments performed by the MTT assay. P values, Student's t-test.
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Results
MTT assay: DEX increased DNR cytotoxicity in K562 and HL60 cell lines and had no influence in patient samples
At the DNR concentration of 1 g/ml, survival of K562 cells incubated with DNR alone or in the combination of DNR + DEX, was 63% ± 5% and 54% ± 4%, respectively (P Ͻ 0.01), in comparison to cells incubated without any drug (Figure 1 ). K562 cells treated with DEX at the concentration of 20 g/ml showed survival of 88 ± 4%, when compared to the cells cultured without drugs (P Ͻ 0.001). For HL60 cell line, incubation of cells with DEX resulted in 93 ± 4% survival (P Ͻ 0.001), while LC50 for cells incubated with DNR alone or in the combination of DNR + DEX, was 0.24 ± 0.03 g/ml and 0.18 ± 0.03 g/ml, respectively (P Ͻ 0.01), in comparison to cells incubated without any drug.
For patient samples (Figure 2) , LC50 values for DNR with and without DEX showed strong correlation (Spearman's rho = 0.818, P = 0.001) and LC50 for DNR did not differ from LC50 for DNR + DEX (Wilcoxon matched paired samples test P = 0.766). When pairs of cytotoxicity values of DNR ± DEX for each sample were analyzed, the cell survival in the presence of DNR without DEX was higher in 22 cases (ie possible cytotoxic DEX effect) and in the other 23 cases the cell survival was higher in the presence of DNR + DEX (ie possible suppression of cytotoxicity by DEX). Median LC50 values for DNR without DEX was 0.46 g/ml, while with DEX it was 0.48 g/ml, and the differences did not show any statistical difference (P = 0.642 Mann-Whitney U test). When the number of living control patient cells were taken as 100%, then the survival of cells cultured with DEX only, was 82 ± 20% (P Ͻ 0.001) in comparison to drug-free cultured cells. We did not observe any impact of disease type and status on differences between cytotoxicity of DNR alone and in combination with DEX. In spite of the fact that AML and relapsed ALL samples were, in general, more resistant to DNR, we did not observe any specific differences in DEX influence on DNR cytotoxicity. Only five leukemic samples showed more than a two-fold difference in sensitivity between DNR and DNR+DEX ( Figure 2 ). In four cases (one pro-B-ALL, one common-ALL, one T-ALL and one AML) cells were more resistant to combination DNR + DEX, and in one case (T-ALL), were more resistant to DNR alone.
Cell cycle: DEX weakly potentiated the effect of DNR in cell lines but not in patient samples
DEX had almost no effect on cell cycle, both in cell lines and in patient samples, while DNR itself caused cell cycle arrest and increased the number of cells in S-phase (P Ͻ 0.05 for cell lines and P Ͻ 0.01 for patient samples). The percentage of cells in S-phase in the presence of DEX + DNR was higher when compared to the percentage of cells in S-phase in respective samples treated with DNR without DEX, in K562 and HL60 cell lines (P Ͻ 0.05), but not in patient samples. The number of necrotic/apoptotic cells, as detected by cell cycle analysis, was not significantly higher after exposure to DEX ± DNR both for cell lines and patient samples (Figure 3 ). No differences in cell cycle were found between leukemia subtypes, both with regard to influence of DNR and the impact of DEX on DNR-induced cell cycle arrest.
Apoptosis: DEX induces apoptosis in patient samples and in HL-60 and K562 cell lines
Cells became positive for annexin V staining after exposure to DEX in K562 cell line (24.5% vs 16.5%, P Ͻ 0.05), in HL60 cell line (21.1% vs 14.9%, P Ͻ 0.05) but not in patient samples (40.2% vs 35.7%, NS). After exposure to DEX + DNR, in comparison to cell exposure to DNR only, induction of annexin V was higher in K562 cell line (46.0% vs 30.2%, P Ͻ 0.05), in HL60 cell line (93.5% vs 86.4%, P Ͻ 0.05) but again, not in patient samples (63.4% vs 61.2%, NS). The percentage of necrotic cells was higher in both cell lines (P Ͻ 0.05 for each cell line) in the presence of DEX vs no drug and DEX+DNR vs DNR (Figure 4) . This difference for patient samples was significant for the effect of DEX without DNR vs drug-free cells (P Ͻ 0.01), and did not reach significance when DNR + DEX was compared to DNR without DEX. The percentage of cells expressing annexin V after exposure to DNR ± DEX did not show statistical differences between leukemia subtypes, however, the number of cells with annexin V expression after treatment with DNR without DEX, showed a tendency to be higher in initial ALL samples than in relapsed ALL and in AML patients.
Discussion
Dexrazoxane (DEX) which is currently used as a cardioprotective agent in combination with DNR and doxorubicin (DOX) was originally developed as an antitumor agent in the 1970s. 5 Previous experiments have explored the ability of DEX to inhibit the catalytic activity of topoisomerase II and it has been found that prolonged exposures to DEX are cytotoxic to human leukemic cells at concentrations that are clinically achievable. 5, 6 In our study, DEX itself exerted a cytotoxic effect and induced the expression of annexin V in both cell lines. Its affect on cell cycle arrest was very weak. When combined with DNR in cell lines, DEX caused higher cytotoxicity of DNR, higher induction of annexin V, higher percentage of necrotic cells and cell cycle arrest by increasing the number of cells in S-phase. Since cytotoxicity of DNR was significantly influenced by DEX in K562 and HL60 cell lines, this finding indicates weak cytotoxicity and either additive or synergistic effect of DEX on DNR cytotoxicity in both cell lines. DEX is known to cause cell cycle arrest at G2/M, 6, 7 however, this effect was almost not observed in our study, regardless of the type of cells which were analyzed.
When patient samples were taken into account, in all three assays the interpatient results have shown great variability; the differences in range were wider for the cytotoxicity assay results and smaller both for annexin V expression and cell cycle arrest. In the group of 45 leukemic patient samples, the effect of DEX was observed on survival of cells not being treated with DNR. The cell survival was lower when the effect caused by DEX was measured by the MTT assay and annexin V expression, but the difference was not obvious when cell cycle was analyzed. The impact of DEX on DNR cytotoxicity, cell cycle and induction of annexin V was minimal and did not show a clear tendency. The cytotoxicity of DNR was weakly higher without DEX, but expression of annexin V, the percentage of necrotic cells and inhibition of cell cycle was weakly higher in the presence of DEX. This might indicate that, in general, DEX neither limits nor potentiates the cytotoxicity of DNR against childhood leukemic cells. All three assays have shown that DEX itself exerts certain cytotoxic effects on leukemic cells. The results of these assays gave comparable results.
The effect of DEX on cells can be related to its molecular mechanism of activity, with the target in topoisomerase II, which is the same target as for DNR. However, when DEX was added to DNR, the effect of DEX was very weak. This was probably because of sufficient topoisomerase II blockade already caused by DNR.
For patient samples we did not see the influence of DEX on cytotoxicity of DNR, which we could observe in cell lines. As there is no pharmacokinetic interaction of dexrazoxane on anthracycline metabolism, 8 the explanation for these discrepancies between cell lines and patient samples is not clear. This may be caused by differences in the blockage of topoisomerase II by DNR; by differences in the level of expression of topoisomerase II between K562 and HL60 cell lines and patient samples, or by variability in topoisomerase II expression in human cells, especially between leukemia subtypes. It can be related to differences in apoptosis pathways, especially caspase activity. In a previous study, it was also suggested that the acquired resistance to DEX in the DZR cell line was caused mainly through an alteration in the topoisomerase II target. 9 In experimental conditions, DEX was also shown to cause a decrease in DNA synthesis by interaction with topoisomerase I-DNA covalent complexes. 10 DEX combined with DOX (plus 5-fluorouracil plus cyclophosphamide in the FAC regimen) led to a significant decrease in doxorubicin cardiotoxicity and a significant increase in median survival time for patients with advanced breast cancer responsive to FAC. 11 As DOX resistance was not induced in the K562 cell line in the presence of DEX for several months, this suggested that DEX could delay the development of MDR1, but did not act as a conventional modulator of P-glycoprotein, thus allowing responders to the FAC regimen to 823 continue to respond.
12 DEX-induced apoptosis in the K562 cell line is probably associated with a caspase-3 activation/cleavage pathway. The ability of DEX to induce differentiation and apoptosis suggests that bisdioxopiperazines may be useful in treating some types of leukemia. 13 In contrast, DEX prevented DNR-induced myocyte apoptosis, but not necrosis caused by higher anthracycline concentrations. The antiapoptotic action of DEX was mimicked by the superoxide-dismutase mimetic porphyrin. 14 The recognition that anthracycline-induced cardiac myocyte apoptosis, perhaps mediated by superoxide anion generation, occurs at concentrations well below those that result in myocyte necrosis, may aid in the design of new therapeutic strategies to limit the toxicity of these drugs.
14 Although the cardioprotective effect of DEX in cancer patients undergoing chemotherapy with anthracyclines is well documented, the potential of this drug to modulate topoisomerase II activity and cellular iron metabolism may hold the key for future applications of DEX in cancer therapy, immunology, or infectious diseases. 15 In conclusion, the results of this study show that DEX, which is an inhibitor of topoisomerase II and prevents forma- Leukemia tion of reactive oxygen species, 16 apart from a cardioprotective effect, also has weak cytotoxic properties. Because the mechanism of its action partially overlaps with the mechanism of DNR cytotoxicity, it seems that in the presence of DNR, the effect of DEX cytotoxicity is very weak, or absent, especially in patient leukemic samples. On the other hand, with the three methods used in the study we did not observe suppressive influence of DEX on DNR cytotoxicity. These results suggest that DEX has no impact on daunorubicin cytotoxicity to childhood leukemic blasts. 
